When considering HFpEFpatients in particular, a study analyzing the effect of the SGLT2 inhibitorsluseogliflozin, empagliflozin and tofogliflozin on left ventricular function inpatients with type 2 diabetes and HFpEF showed that these drugs led to asignificant decrease in E/A ratios and E/e’ ratios after treatment [51]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.